Drug intelligence / Profile preview

NK-091

Development stage: Preclinical
Lead developer: Shanghai Enkai Cell Technology
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies

Overview

NK-091 is a synthetic/engineered natural killer (NK) cell therapy (Syn-NK+) being developed by Shanghai NK Cell Technology (Shanghai Enkai Cell Technology Co. Ltd.) for the treatment of unspecified tumors. It is currently in the discovery/preclinical development phase. The therapy utilizes a proprietary 'Syn-NK+' engineering approach, which likely involves synthetic biology modifications to enhance the anti-tumor efficacy of NK cells, though specific molecular targets and mechanisms of action have not been publicly disclosed.

Beyond the preview

Go deeper on NK-091.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NK-091.

Explore the full profile